EP0337498A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Method for determining state of disease progression
Assignee: Montefiore Medical Center
•
Filing: 1989-04-17
•
Granted: —
•
Expires: 2009-04-17
Abstract
Abstract The present invention relates to a method for determining the state of disease progression thereby providing a means for the detection of said disease and in the risk evaluation for the development of said disease. In particular, the present invention contemplates a method for determining and monitoring the state of malignant or premalignant progression or risk of development of malignant or premalignant progression in mammalian tissue or cells. In particular, the present invention is directed to benign and malignant colon tumors and benignly and malignantly transformed colon cells. The present invention is predicated on the discovery that the abundance of specific first nucleic acids changes in response to the disease state. The present invention is also directed to recombinant second nucleic acids useful in the detection and quantification of the first nucleic acids by hybridization. The present invention also contemplates the use of polypeptides encoded by said second nucleic acids in the regression and prophylaxis of disease states.
Inventors
- 👤 Leonard H. Augenlicht
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-05 07:22
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/30; C07K16/3046; C07K14/00; C07K14/435; C07K14/46; C07K14/47; C12; C12Q; C12Q1/00; C12Q1/68; C12Q1/6876; C12Q1/6883; C12Q1/6886; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/575; G01N33/5753; C12Q2600/00; C12Q2600/112
Claims Analysis
Total Claims: 31
Claim 1
Independent Claim
48 words
A method for determining and monitoring the state of malignant or premalignant progression or risk for development of malignant or premalignant progression in mammalian tissues which comprises identifying statistically significant differential in detected abundance of an RNA isolated from the tissue to be studied relative to a standard.
Claim 2
Independent Claim
48 words
A method for determining and monitoring the state of malignant or premalignant progression or risk for development of malignant or premalignant progression in mammalian tissues which comprises identifying statistically significant differential in detected abundance of an RNA isolated from the tissue to be studied relative to a standard.
Claim 3
Dependent Claim
26 words
The method according to Claim 1 wherein said RNA is represented in a first nucleic acid isolated from said tissue and immobilized onto a solid support.
Claim 4
Dependent Claim
39 words
The method according to Claim 1 wherein a second nucleic acid, or part thereof, will hybridize to said RNA, or part thereof, said second nucleic acid characterized by possessing a copy number variably represented in different normal mammalian tissues.
Claim 5
Dependent Claim
25 words
The method according to Claim 3 wherein the hybridization is quantified by exposing said second nucleic acid contacted with said RNA to a detecting means.
Claim 6
Dependent Claim
116 words
A method for determining the state of malignant or premalignant progression or risk for development of malignant or premalignant progression in mammalian tissue or cells as defined in Claim 1 comprising determining the relative abundance of an RNA, said RNA being represented in a first nucleic acid isolated from the tissue to be studied by contacting to said first nucleic acid, a second nucleic acid in probe form, said second nucleic acid characterized by possessing a copy number variably represented in different normal mammalian tissues, such that the second nucleic acid, or part thereof, will hybridize to said RNA, the hybridization quantified by exposing said second nucleic acid contacted with said RNA to a detecting means.
Claim 7
Dependent Claim
13 words
The method according to Claim 5 wherein said mammalian tissue is human tissue.
Claim 8
Dependent Claim
16 words
The method according to Claim 6 wherein said human tissue is derived from human colonic mucosa.
Claim 9
Dependent Claim
15 words
The method according to Claim 5 wherein said first nucleic acid comprises total cellular RNA.
Claim 10
Dependent Claim
45 words
The method according to Claim 5 wherein the second nucleic acid probe is labeled with a material which generates a signal, said material being selected from the group consisting of a radioactive isotope, an enzyme, a fluorescent molecule, a chemiluminescent molecule and a bioluminescent molecule.
Claim 11
Dependent Claim
28 words
The method according to Claim 5 wherein the detecting means is selected from the group consisting of x-ray film, an enzyme substrate and a device for detecting luminescence.
Claim 12
Dependent Claim
20 words
The method according to Claim 5 wherein said nucleic acid is complementary DNA (cDNA) to RNA derived from malignant tissue.
Claim 13
Dependent Claim
27 words
The method according to Claim 11 wherein said cDNA is maintained in a culture of Escherichia coli , accorded the ATCC accession number 67674, and designated 50F1.
Claim 14
Dependent Claim
18 words
The method according to Claim 11 or 12 wherein said cDNA is characterized by the following nucleotide sequence:
Claim 15
Dependent Claim
8 words
A cDNA characterized by the following nucleotide sequence:
Claim 16
Dependent Claim
8 words
A cDNA characterized by the following nucleotide sequence:
Claim 17
Dependent Claim
14 words
The cDNA according to Claim 14 wherein said cDNA is contained in a vector.
Claim 18
Dependent Claim
24 words
The cDNA according to Claim 15 wherein the vector is selected from the group consisting of a plasmid, a cosmid and a viral vector.
Claim 19
Dependent Claim
21 words
The cDNA according to Claim 16 wherein said vector is capable of replicating in a eukaryotic host or a prokaryotic host.
Claim 20
Dependent Claim
11 words
The cDNA according to Claim 16 wherein the vector is pBR322.
Claim 21
Dependent Claim
26 words
The cDNA according to Claim 17 wherein the host is selected from the group consisting of bacteria, mammalian cells, yeast cells, fungal cells and insect cells.
Claim 22
Dependent Claim
12 words
A host transformed with the cDNA according to Claim 18 or 19.
Claim 23
Dependent Claim
23 words
The host according to Claim 20 wherein said host has the identifying characteristics of Escherichia coli and accorded the ATCC accession number 67674.
Claim 24
Dependent Claim
10 words
A polypeptide encoded by the cDNA according to Claim 14.
Claim 25
Dependent Claim
31 words
A pharmaceutical composition useful in inducing regression or inhibiting growth of colonic cancer in a mammal comprising an effective amount of polypeptide according to Claim 22 and a pharmacologically acceptable carrier.
Claim 26
Dependent Claim
37 words
A pharmaceutical composition useful in inducing regression or inhibiting growth of colonic cancer in a mammal comprising an effective amount of first nucleic acid according to Claim 5 and a pharmacologically acceptable second nucleic acid carrier molecule.
Claim 27
Dependent Claim
13 words
An antibody to the polypeptide, or a part thereof, according to Claim 22.
Claim 28
Dependent Claim
16 words
The antibody according to Claim 25 wherein said antibody is a monoclonal or a polyclonal antibody.
Claim 29
Dependent Claim
55 words
A method for detecting the polypeptide according to Claim 22 in human colonic mucosa comprising the steps of contacting the tissue or tissue extract to be tested with an antibody to said polypeptide, or part thereof, for a time sufficient for a polypeptide-antibody complex to form and subjecting said polypeptide-antibody complex to a detecting means.
Claim 30
Dependent Claim
41 words
The method according to Claim 27 wherein said antibody is labelled with a material providing a detectable signal, said material selected from the group consisting of a radioactive isotope, an enzyme, a fluorescent molecule, a chemiluminescent molecule or a bioluminescent molecule.
Claim 31
Dependent Claim
37 words
The method according to Claim 27 or 28 wherein the polypeptide-antibody complex is detected by a second antibody, said second antibody being directed to the first antibody, wherein said second antibody being labelled with a detectable signal.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.